Overview Spermidine Anti-Hypertension Study Status: Recruiting Trial end date: 2022-11-15 Target enrollment: Participant gender: Summary The impact of daily spermidine application on arterial blood pressure and other secondary parameters will be evaluated in a double-blind single center 46 patients cross-over study. Phase: Phase 3 Details Lead Sponsor: Medical University of GrazCollaborators: ETH ZurichInstitut National de la Santé Et de la Recherche Médicale, FranceUniversity Hospital TuebingenUniversity of Graz